Why the study?
Does percutaneous mitral balloon valvuloplotomy yield different long-term event-free survival in patients with moderate versus severe mitral stenosis?
Does percutaneous mitral balloon valvuloplotomy yield different long-term event-free survival in patients with moderate versus severe mitral stenosis?
Long-term (10-year) event-free survival after percutaneous mitral balloon valvuloplotomy is similar between patients with moderate and severe mitral stenosis, suggesting the procedure for moderate MS should be reserved for selected cases with favorable morphology.
Background and Objectives:Percutaneous mitral balloon valvuloplotomy (PMV) is a safe and effective procedure for the treatment of mitral stenosis (MS); however, its long-term results according to the severity of MS remain unknown. The aim of this study was to compare the long-term results of PMV between moderate and severe MS. Subjects and Methods:The immediate and long-term outcomes of 786 patients (198 male, mean age; 43 years) who underwent PMV at a single referral center, between 1988 and 2000, were analyzed. The clinical and echocardiographic data were compared between moderate (n=357) and severe MS (n=429). Results:Optimal results were gained in 618 (79%) patients, including 80 and 76% moderate and severe MS cases, respectively (p=0.13). Acute complications occurred in 85 patients (11%), but without significant difference between the two groups. After a mean follow-up period of 94 months (range, 6 to 210 month), the 5 year event-free survival rate was better in moderate (88%) than in severe MS (79%), but the 10 year event-free survival rates were no different (65% vs. 65%). Independent predictors for better prognosis were a lower echo score (≤8)(p=0.017, HR= 0.67), a larger mitral valve area after the PMV (≥1.7 cm)(p=0.002, HR=0.65), less mitral regurgitation (<grade III) (p=0.001, HR=0.46) and a lower left atrial pressure (<12 mmHg)(p=0.005, HR=0.80). Conclusion:The immediate and long-term outcomes of PMV for moderate MS were no better after 9 years than those for severe MS. Therefore, PMV for moderate MS should be considered in selected cases with a favorable MV morphology. (Korean Circulation J 2006;36:208-213)
No takes yet. Share an insight, caveat, or question.
Kim et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: